Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 27,167 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.83, for a total value of $538,721.61. Following the sale, the chief financial officer now owns 473,433 shares of the company’s stock, valued at $9,388,176.39. The trade was a 5.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $19.75 on Thursday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $17.05 and a fifty-two week high of $39.83. The business has a 50 day moving average price of $21.04 and a two-hundred day moving average price of $22.55. The firm has a market cap of $2.46 billion, a PE ratio of -3.93 and a beta of 0.97.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Commonwealth Equity Services LLC boosted its stake in Arrowhead Pharmaceuticals by 3.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock valued at $901,000 after acquiring an additional 1,250 shares during the last quarter. Rhumbline Advisers grew its stake in Arrowhead Pharmaceuticals by 2.9% in the second quarter. Rhumbline Advisers now owns 383,029 shares of the biotechnology company’s stock worth $9,955,000 after purchasing an additional 10,924 shares in the last quarter. TD Asset Management Inc increased its holdings in Arrowhead Pharmaceuticals by 90.8% in the second quarter. TD Asset Management Inc now owns 54,200 shares of the biotechnology company’s stock valued at $1,409,000 after buying an additional 25,800 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 67.3% in the second quarter. Victory Capital Management Inc. now owns 41,090 shares of the biotechnology company’s stock valued at $1,068,000 after buying an additional 16,534 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in Arrowhead Pharmaceuticals by 2.4% during the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock valued at $901,000 after buying an additional 821 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ARWR shares. Chardan Capital reiterated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Citigroup decreased their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, December 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Hold” and a consensus price target of $43.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.